Literature DB >> 24738674

Daclatasvir plus sofosbuvir for HCV infection.

Mark S Sulkowski, Ira M Jacobson, David R Nelson.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2014        PMID： 24738674     DOI： 10.1056/NEJMc1401726

Source DB:  PubMed          Journal:  N Engl J Med        ISSN： 0028-4793            Impact factor:   91.245


× No keyword cloud information.
  22 in total

1.  Impact of IFNL4 rs12979860 and rs8099917 polymorphisms on response to Peg-Interferon-α and Ribavirin in patients with congenital bleeding disorder and chronic hepatitis C.

Authors:  Maryam Keshvari; Seyed Moayed Alavian; Bita Behnava; Ali Pouryasin; Johanna C Craig; Heidar Sharafi
Journal:  J Clin Lab Anal       Date:  2016-10-13       Impact factor: 2.352

2.  Hepatitis C: Treatment triumphs.

Authors:  Charles M Rice; Mohsan Saeed
Journal:  Nature       Date:  2014-06-05       Impact factor: 49.962

3.  Direct Acting Anti-hepatitis C Virus Drugs: Clinical Pharmacology and Future Direction.

Authors:  Ayman Geddawy; Yasmine F Ibrahim; Nabil M Elbahie; Mohammad A Ibrahim
Journal:  J Transl Int Med       Date:  2017-03-31

4.  The Synthetic Antiviral Drug Arbidol Inhibits Globally Prevalent Pathogenic Viruses.

Authors:  Eve-Isabelle Pécheur; Viktoriya Borisevich; Peter Halfmann; John D Morrey; Donald F Smee; Mark Prichard; Chad E Mire; Yoshihiro Kawaoka; Thomas W Geisbert; Stephen J Polyak
Journal:  J Virol       Date:  2016-01-06       Impact factor: 5.103

Review 5.  Hepatitis C in non-hepatic solid organ transplant candidates and recipients: A new horizon.

Authors:  Sara Belga; Karen Elizabeth Doucette
Journal:  World J Gastroenterol       Date:  2016-01-28       Impact factor: 5.742

Review 6.  Daclatasvir-containing all-oral regimens for the treatment of hepatitis C virus infection.

Authors:  Sheng-Shun Yang; Jia-Horng Kao
Journal:  Hepatol Int       Date:  2015-11-05       Impact factor: 6.047

Review 7.  Advances in hepatitis C therapy: What is the current state - what come's next?

Authors:  Steffen Zopf; Andreas E Kremer; Markus F Neurath; Juergen Siebler
Journal:  World J Hepatol       Date:  2016-01-28

8.  Inhibition of hepatitis C virus using siRNA targeted to the virus and Hsp90.

Authors:  Ana Claudia Silva Braga; Bruno Moreira Carneiro; Mariana Nogueira Batista; Mônica Mayumi Akinaga; Paula Rahal
Journal:  Cell Stress Chaperones       Date:  2016-11-17       Impact factor: 3.667

9.  Clinical Resistance to Velpatasvir (GS-5816), a Novel Pan-Genotypic Inhibitor of the Hepatitis C Virus NS5A Protein.

Authors:  Eric J Lawitz; Hadas Dvory-Sobol; Brian P Doehle; Angela S Worth; John McNally; Diana M Brainard; John O Link; Michael D Miller; Hongmei Mo
Journal:  Antimicrob Agents Chemother       Date:  2016-08-22       Impact factor: 5.191

Review 10.  Interferon-Free Hepatitis C Treatment before and after Liver Transplantation: The Role of HCV Drug Resistance.

Authors:  Bruno Roche; Audrey Coilly; Anne-Marie Roque-Afonso; Didier Samuel
Journal:  Viruses       Date:  2015-09-23       Impact factor: 5.048
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.